氟哌噻吨美利曲辛片辅助莫沙必利治疗功能性消化不良的疗效

doi:10.3969/j.issn.1001-8131.2022.01.009

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (427 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the curative effect of flupentixol and melitracen tablets combined with mosapride in the treatment of functional dyspepsia（FD）. Methods 128 patients with FD treated were randomly divided into group A（65 cases）and group B（63 cases）.Group A were treated with flupentixol and melitracen tablets combined with mosapride,while group B orally took mosapride.The curative effect and adverse reactions were observed.The gastric emptying rates and gastrointestinal hormones [vasoactive intestinal peptide（VIP）,substance P（SP）,motilin（MTL）] before and after treatment were compared between the two groups. Results The total response rate in group A was 93.85%,higher than 80.95% in group B（P<0.05）.After treatment,the gastric emptying rates of the two groups increased significantly,and group A had a higher gastric emptying rate than group B（P<0.05）.After treatment,VIP decreased significantly,while SP and MTL increased significantly,all of which were better in group A than in group B（P<0.05）.There was no significant difference in the incidence of adverse reactions between the two groups（10.77% vs.6.35%）（P>0.05））. Conclusion Flupentixol and melitracen tablets combined with mosapride is effective in the treatment of FD,which can significantly improve the patients' gastrointestinal hormone levels and gastric emptying rate,with high safety.

Key words： Flupentixol and melitracen Mosapride Functional dyspepsia Gastric emptying

Received: 05 December 2020

PACS:

R573.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Dan

Cite this article:

Li Dan. Curative Effect of Flupentixol and Melitracen Tablets Combined With Mosapride in the Treatment of Functional Dyspepsia[J]. journal1, 2022, 42(1): 20-22.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2022.01.009 OR http://www.hrbyybjb.org.cn/EN/Y2022/V42/I1/20

[1] Vandenberghe A,Schol J,Van den HK,et al.Current and emerging therapeutic options for the management of functional dyspepsia[J].Expert Opin Pharmacother,2020,21(3):365-376.
[2] 汤玉茗,袁耀宗.中国功能性消化不良专家共识意见(2015年,上海)解读:药物治疗[J].中华消化杂志,2016,36(4):237-238.
[3] 张静,王智凤,皮艳娜,等.枸橼酸莫沙必利对功能性消化不良的临床疗效评价[J].中华消化杂志,2017,37(12):845-847.
[4] 汤净,陈军,谭琰,等.氟哌噻吨美利曲辛片联合常规治疗对功能性消化不良效果观察[J].临床消化病杂志,2016,28(1):16-19.
[5] 董丽娟,贺继东,赵文亭,等.莫沙必利联合氟哌噻吨美利曲辛治疗功能性消化不良对患者近端胃舒张及胃排空功能影响分析[J].临床误诊误治,2020,33(3):48-52.
[6] 罗马委员会.功能性胃肠病的罗马Ⅲ诊断标准[J].现代消化及介入诊疗,2007,12(2):137-140.
[7] 张玲,蔡媛媛,麦联任.氟哌噻吨美利曲辛片联合莫沙必利治疗功能性消化不良的临床研究[J].中国临床药理学杂志,2019,35(18):2010-2012.
[8] 陈艳黎,路志术,郑艳玲,等.功能性消化不良行枸橼酸莫沙必利分散片联合黛力新治疗的临床疗效[J].现代消化及介入诊疗,2016,21(4):626-628.
[9] 卢眺眺,朱翔贞,高静芳.功能性消化不良伴焦虑抑郁情绪的研究进展[J].长春中医药大学学报,2016,32(2):437-440.
[10] 范明霞,林游游,许浩云,等.枸橼酸莫沙必利片在中国健康受试者体内的药代动力学及生物等效性研究[J].中国临床药理学杂志,2019,35(19):2364-2368.
[11] 张洁,窦钰静.功能性消化不良患者120例精神心理影响因素调查分析与干预对策[J].山西医药杂志,2019,48(11):1289-1291.
[12] 张殿华,司益民,卫团利.氟哌噻吨美利曲辛片联合常规治疗对功能性消化不良疗效分析[J].深圳中西医结合杂志,2017,27(23):98-100.
[13] 安万杰,苏高建,胡静.枸橼酸莫沙必利分散片联合氟哌噻吨美利曲辛片治疗功能性消化不良的临床疗效观察[J].实用临床医药杂志,2017,21(21):189-190.